Director, Research and Development, Nimble Therapeutics
High-Throughput Discovery and Parallel Optimization of Peptide Therapeutics
We have developed a peptide synthesis and screening platform for the discovery of peptidic molecules that bind to protein targets of interest. This technique employs the use of digital micromirror devices to direct the maskless synthesis of millions of unique peptides in parallel on a microarray surface. Using a chemical catalog of over 300 amino acid building blocks (natural and non-natural), we can synthesize 18 million unique peptides in less than 48 hours. The method can be applied to synthesize both linear and cyclic peptidic molecules, enabling screens in a diverse chemical space. Here, we will describe the core technology and its application to rapidly and systematically evolve high-affinity, high-specificity binding peptidomimetics to protein targets in a reproducible and digitally controlled process.
Lauren Goodrich is the Director of Research and Development at Nimble Therapeutics. Prior to joining Nimble, Dr. Goodrich led the development of drug discovery applications of Nimble’s peptide microarray platform at Roche Madison. She holds a Ph.D. in chemistry from the University of Michigan.